Arthneeti
All Q2 FY26 results →
CH

Cardinal Health, Inc.

Q2 FY26Health Care Providers and Services

Cardinal Health, Inc. Q2 FY26 Results — Earnings Call Analysis

Q2 FY26 earnings call: what management said on revenue, margins and capex.

Price₹200
Market cap₹46.8K Cr
P/E30.6
Updated29 May 2026
Read4 min read

Cardinal Health, Inc. Q2 FY26 key numbers

Revenue
Specialty business expected to grow over 20% in revenue, with Specialty revenue forecasted to exceed $50 billion in fiscal 2026.

As stated in Cardinal Health, Inc.'s Q2 FY26 earnings call transcript · published 29 May 2026. Reported figures, not investment advice.

The short version

- Specialty business expected to grow over 20% in revenue, with Specialty revenue forecasted to exceed $50 billion in fiscal 2026 (Pages 3,7). - Confident in long-term targets with expected 12% to 14% non-GAAP EPS growth.

From Cardinal Health, Inc.'s Q2 FY26 earnings-call transcript · updated 29 May 2026.

Revenue & Sales Performance

Good growth
  • Specialty business expected to grow over 20% in revenue, with Specialty revenue forecasted to exceed $50 billion in fiscal 2026 (Pages 3,7).
  • Continued strong demand and demographic trends support positive outlook in Pharmaceutical and Specialty Solutions segments (Page 4).
  • Growth in other businesses such as at-Home Solutions, Nuclear and Precision Health, and OptiFreight Logistics with revenue up 31% and profit up 34% (Pages 3,7).
  • GMPD segment projecting 1% to 3% revenue growth; focus on cost efficiencies and supply chain resilience (Page 4).
  • Positive contribution expected from annualization of Solaris acquisition and synergy realization (Page 4).

2 more points from Cardinal Health, Inc.'s call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Cardinal Health, Inc. said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

Capex planned
  • Investing in infrastructure, technology, and people to improve core Pharma segment, including automation and productivity initiatives in distribution centers.
  • Expansion of at-Home Solutions network capacity, offerings, and technology to drive efficiency and customer experience.
  • Progressing with a new Sacramento distribution center lease to better serve West Coast customers.
  • Expansion of Actinium-225 production capabilities at Center for Theranostics to support growing demand for targeted cancer therapies.
  • Continued investments in technology and core distribution footprint to support growth across Specialty and other businesses.

2 more points from Cardinal Health, Inc.'s call on capex

Create a free account to keep reading this call

Fundraising & Capital Structure

See what Cardinal Health, Inc. said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

There is relevant information related to business volumes and contract ramp-ups that may indirectly reflect on order flow: - Solaris distribution volume is currently in the process of ramping up with the pharma business; impact on fiscal ’26 expected to be not material but positive moving forward (Page 14). - Ion and GIA distribution contracts have been achieved and volumes are coming in as expected, but their impact is modeled separately from financial guidance (Page 14).

2 more points from Cardinal Health, Inc.'s call on order book

Create a free account to keep reading this call

What the Q2 FY26 call signalled

2 of 3 strong

RevenueGood growth
MarginMargins steady
CapexCapex planned

Continue your research

Others in Health Care Providers and Services this season

  • BrightSpring Health Services, Inc. (Q2 FY26)

    BrightSpring Health Services, Inc. Q2 FY26 quarterly results analysis. Pharmacy Solutions expected to see balanced sequential revenue and EBITDA growth througho

  • DaVita Inc. (Q2 FY26)

    DaVita Inc. Q2 FY26 quarterly results analysis. Treatment volume guidance raised from flat to 25-50 basis points growth for 2026, driven by better underlying pe

  • Tenet Healthcare Corporation (Q2 FY26)

    Tenet Healthcare Corporation Q2 FY26 quarterly results analysis. Hospital segment expects a 10% normalized year-over-year adjusted EBITDA growth in 2026, suppor

  • Guardant Health, Inc. (Q2 FY26)

    Guardant Health, Inc. Q2 FY26 quarterly results analysis. Sales team started this year with ~300 reps; incremental gross profit will be reinvested in expanding

Compare:vs UnitedHealth Group Incorporatedvs McKesson Corporationvs Elevance Health, Inc.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Cardinal Health, Inc. and 15K+ more earnings calls,
for less than your morning chai

a day

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Cardinal Health, Inc. Q2 FY26 results?

- Specialty business expected to grow over 20% in revenue, with Specialty revenue forecasted to exceed $50 billion in fiscal 2026 (Pages 3,7). - Confident in long-term targets with expected 12% to 14% non-GAAP EPS growth.

What is Cardinal Health, Inc. share price analysis?

Cardinal Health, Inc. currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 30.6 with a market cap of $46,806. Investors should review the full earnings analysis for detailed insights.

Is Cardinal Health, Inc. planning capital expenditure?

- Investing in infrastructure, technology, and people to improve core Pharma segment, including automation and productivity initiatives in distribution centers.

Keep Cardinal Health, Inc. on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.